Lanoxicaps

Ventricular Arrhythmia, Congestive Heart Failure, Atrial Fibrillation + 2 more

Treatment

20 Active Studies for Lanoxicaps

What is Lanoxicaps

Digoxin

The Generic name of this drug

Treatment Summary

Digoxin is a medication used to treat atrial fibrillation and heart failure symptoms. It was first approved by the FDA in 1954 and comes from the foxglove plant, which was studied by an English physician and botanist in the 1780s. This plant has been used to make medications since the 1250s, and Digoxin is one of the oldest cardiovascular medications still in use today.

Digoxin

is the brand name

image of different drug pills on a surface

Lanoxicaps Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Digoxin

Digoxin

1975

190

Effectiveness

How Lanoxicaps Affects Patients

Digoxin is a medication that can help people with an irregular heartbeat (atrial fibrillation) by increasing the force of their heartbeat and slowing down their heart rate. Studies have shown that taking digoxin can lead to improved exercise capacity and fewer hospitalizations or emergency visits due to heart failure. However, it has a narrow therapeutic window and can cause potentially fatal side effects, such as ventricular fibrillation or complete heart block, in individuals who have pre-existing sinus node disease or AV block and take digoxin.

How Lanoxicaps works in the body

Digoxin helps the heart work better by decreasing the heart rate and increasing the force of heart muscle contractions. It does this by blocking a protein that regulates the entry and exit of sodium, potassium and calcium into and out of cells. This increases the amount of sodium and calcium in the cells of the heart muscle, making it stronger. Digoxin also stimulates the parasympathetic nervous system, which decreases neurohormonal activity and lowers the heart rate.

When to interrupt dosage

The suggested dose of Lanoxicaps is contingent upon the diagnosed condition, including Chronic Atrial Fibrillation, mild, moderate Heart Failure and Congestive Heart Failure. The dosage fluctuates as per the method of delivery (e.g. Oral or Liquid - Oral) featured in the table beneath.

Condition

Dosage

Administration

Heart failure

0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL

, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection - Intramuscular; Intravenous, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection, Capsule - Oral, Capsule, Capsule, liquid filled

Congestive Heart Failure

0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL

, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection - Intramuscular; Intravenous, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection, Capsule - Oral, Capsule, Capsule, liquid filled

Atrial Fibrillation

0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL

, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection - Intramuscular; Intravenous, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection, Capsule - Oral, Capsule, Capsule, liquid filled

Myocardial contractility

0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL

, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection - Intramuscular; Intravenous, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection, Capsule - Oral, Capsule, Capsule, liquid filled

Ventricular Arrhythmia

0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL

, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection - Intramuscular; Intravenous, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection, Capsule - Oral, Capsule, Capsule, liquid filled

Warnings

Lanoxicaps has three contraindications, and therefore should not be utilized while encountering any of the conditions outlined in the following table.

Lanoxicaps Contraindications

Condition

Risk Level

Notes

Ventricular Fibrillation

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Digoxin may interact with Pulse Frequency

Severe Hypersensitivity Reactions

Do Not Combine

Digoxin may interact with Pulse Frequency

There are 20 known major drug interactions with Lanoxicaps.

Common Lanoxicaps Drug Interactions

Drug Name

Risk Level

Description

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Digoxin is combined with Hydroxyzine.

Mobocertinib

Major

The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mobocertinib.

Revefenacin

Major

Digoxin may decrease the excretion rate of Revefenacin which could result in a higher serum level.

Ziprasidone

Major

The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ziprasidone.

Abexinostat

Minor

The risk or severity of QTc prolongation can be increased when Digoxin is combined with Abexinostat.

Lanoxicaps Toxicity & Overdose Risk

The lowest toxic dose of digoxin for women is 100 micrograms per kilogram, and for men is 75 micrograms per kilogram. In rats, the lowest toxic dose is 28270 micrograms per kilogram. Taking too much digoxin can lead to nausea, vomiting, changes in vision, and irregular heartbeats. People who are older, have a lower body weight, or have decreased kidney function and electrolyte imbalances are at higher risk of digoxin toxicity.

image of a doctor in a lab doing drug, clinical research

Lanoxicaps Novel Uses: Which Conditions Have a Clinical Trial Featuring Lanoxicaps?

308 active trials are currently in progress to assess the ability of Lanoxicaps to address Cardiac Arrhythmias, boost Myocardial contractility, and manage Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Congestive Heart Failure

181 Actively Recruiting

Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 3, Phase 4

Myocardial contractility

0 Actively Recruiting

Atrial Fibrillation

0 Actively Recruiting

Heart failure

0 Actively Recruiting

Ventricular Arrhythmia

7 Actively Recruiting

Not Applicable, Phase 3, Phase 4

Lanoxicaps Reviews: What are patients saying about Lanoxicaps?

5

Patient Review

6/7/2009

Lanoxicaps for Ventricular Rate Control in Atrial Fibrillation

I had used this type Lanoxin for years without any problems. They took it off the market and I have since had severe reactions to regular Lanoxin. I want to know if it has been put back on the market and if it is now available.

5

Patient Review

7/10/2008

Lanoxicaps for A Type of Fast Heartbeat - Paroxysmal Atrial Tachycardia

I'm extremely disappointed that Glaxo Smith Kline has stopped making this medication. It helped me and I know it's helped other people too. We should have been notified ahead of time so we could have prepared.

5

Patient Review

11/23/2009

Lanoxicaps for Chronic Heart Failure

I've taken Lanoxicaps for over a decade and it's been incredibly effective for me. I had to switch to the Lanoxin form of the drug when Lanoxicaps were taken off the market, but I've since had allergic reactions and other bad reactions to the tablet. It's really unfortunate that there are now fewer medical options for patients with serious cardiac diseases.

5

Patient Review

6/3/2008

Lanoxicaps for Ventricular Rate Control in Atrial Fibrillation

I was very upset when they took Lanoxicaps off the market.

4.7

Patient Review

12/11/2007

Lanoxicaps for Ventricular Rate Control in Atrial Fibrillation

I'm not sure why this product is no longer available, but my doctor switched me to Atenolol.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lanoxicaps

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What's Digoxin used for?

"UK

Digoxin is a medication used to treat irregular heartbeats."

Answered by AI

What's the generic name for Digoxin?

"The oral tablet form of digoxin is available as both a generic drug and a brand-name drug called Lanoxin. An oral solution of digoxin is also available. Digoxin is used to treat atrial fibrillation, mild to moderate heart failure in adults, and heart failure in children."

Answered by AI

What is Lanoxin used for?

"Digoxin is a medication that is used to treat heart failure and certain types of irregular heartbeat. treating heart failure with digoxin can help improve the patient's ability to walk and exercise, as well as the strength of the heart."

Answered by AI

What are the side effects of Digoxin?

"... , Swelling of your liver ...

You may have Covid-19 if you're feeling confused, dizzy or generally unwell. Other symptoms include feeling or being sick (nausea or vomiting) and loss of appetite, diarrhoea, changes in your vision (including blurred vision and not being able to look at bright light), skin rashes, swelling of your liver."

Answered by AI

Clinical Trials for Lanoxicaps

Image of University of Colorado Anschutz in Denver, United States.

HEROIC Program for Heart Failure

18+
All Sexes
Denver, CO

This study will test the mechanisms of a multi-component, nurse-led, primary palliative care intervention, HEart failure Resilience Intervention for Caregivers (HEROIC) to improve caregiver mental well-being, patient health-related quality of life and unplanned acute care in the setting of advanced heart failure. The investigators will conduct a multi-site, randomized controlled trial to test proposed mechanisms of action in a large sample (N=500) of persons with heart failure and the caregivers. The investigators will also examine variation in response to HEROIC components by heart failure subgroup (ventricular assist device, heart transplant or medically managed heart failure).

Phase 2
Waitlist Available

University of Colorado Anschutz (+1 Sites)

Martha Abshire Saylor, PhD, RN

Image of Norton Heart & Vascular Institute - Advanced Heart Failure & Recovery Program in Louisville, United States.

Values-Based Communication for Heart Failure

18 - 105
All Sexes
Louisville, KY

Living with heart failure for adults over age 50 is hard. Older adults have to take many medicines to address heart failure and other health problems. That group of individuals must decide which medications to take and which devices to use to support heart health. Doctors, nurses, and social workers help patients understand these options but do not always know what is most important to them. Talking with patients about what the patients are hoping for, what the patients are worried about, and how much the patients understand about the illness is called a serious illness conversation, and it is hard to do. Doctors, nurses, and social workers are very busy and worry about upsetting patients by bringing up hard topics. The Serious Illness Care Program helps doctors, nurses, and social workers have these conversations by giving the staff a script to follow on what to say. The program also includes ways to make sure staff remember to have the conversation, a brief training, and how to document what is said during the conversation. But, nobody has studied the Serious Illness Care Program in a heart failure clinic, so it has not been customized to meet the needs of heart failure teams or older adults with heart failure. Many programs that are supposed to help patients fail in the real world. One reason is that patients do not include the needs of those who will receive and deliver it. Before this project, the team interviewed heart failure doctors, nurses, social workers, and other staff at a heart failure clinic. As well as interviewing older adults and care partners. The team asked staff how the Serious Illness Care Program can be changed to fit the needs and work in the clinic. The program includes a conversation guide that helps the team know what to say, so the study team asked patients and care partners what the thoughts on the language used and the topics covered. Then, the team practiced putting the program in place at the clinic and trained clinicians on using the Serious Illness Care Program with older adults and family members. Now the team wants to see if the heart failure team likes it and if it is doable. The team will also ask patients and care partners about the conversation and about feelings of anxiety before, during, and after the conversation. Lastly, the team will ask the individuals before and after the conversation about patients' knowledge of heart failure and how prepared the care partner feels to care for the individual. The team also want to explore how the program helps clinicians understand patients' symptoms, quality of life, and illness knowledge. Ultimately, this project establishes a structured framework to facilitate goals-of-care discussions between heart failure teams, patients, and families. These conversations empower patients to make immediate and future medical decisions aligned with personal values and lifestyle preferences. This values-based decision-making process optimizes care delivery and supports patients in achieving optimal health outcomes.

Waitlist Available
Has No Placebo

Norton Heart & Vascular Institute - Advanced Heart Failure & Recovery Program

Have you considered Lanoxicaps clinical trials?

We made a collection of clinical trials featuring Lanoxicaps, we think they might fit your search criteria.
Go to Trials
Image of MemorialCare Long Beach Medical Center in Long Beach, United States.

Vivio System for Heart Failure

18+
All Sexes
Long Beach, CA

The purpose of the study is to examine the Vivio System's ability to track heart failure status in subjects, and compare the Vivio System's measurements to CardioMEMS measurements. Heart failure, which is a form of heart disease, is a condition where the heart does not pump enough blood through the body, resulting in the body not getting the amount of oxygen and nutrients it needs. This research study will collect data using CardioMEMS and the Vivio System in subjects over the age of 21 with a currently implanted, or scheduled to be implanted, CardioMEMS device. This group of individuals will provide researchers with important data because the measurements of their health information can be used to determine if the Vivio is as effective at tracking heart failure status as CardioMEMS. This research study is designed to develop new knowledge, and does not provide a direct benefit to study subjects

Waitlist Available
Has No Placebo

MemorialCare Long Beach Medical Center (+3 Sites)

Ventric Health, LLC

Image of Phoenix VA Health Care System, Phoenix, AZ in Phoenix, United States.

Virtual Palliative Care for Heart Failure or COPD

18+
All Sexes
Phoenix, AZ

Many Veterans living with heart failure or chronic obstructive pulmonary disease (COPD) experience significant symptoms - such as breathlessness, fatigue, depression, and anxiety -that reduce their quality of life. Despite how common these symptoms are, they are often not adequately addressed in routine care. This study tests whether a virtual team of a nurse and social worker can improve quality of life, depression, anxiety, and other patient-reported outcomes for Veterans with heart failure or COPD who are at high risk of hospitalization or death. The nurse helps Veterans manage their most bothersome symptoms using a structured approach, and the social worker provides brief counseling to address emotional and psychological concerns. Both work closely with the Veteran's primary care provider and palliative care clinician to coordinate additional care as needed. The study also examines whether enhanced implementation support helps VA sites adopt the program more successfully compared to standard implementation support.

Waitlist Available
Has No Placebo

Phoenix VA Health Care System, Phoenix, AZ (+6 Sites)

David Bekelman, MD MPH

Image of Rocky Mountain Regional VA Medical Center, Aurora, CO in Aurora, United States.

Pharmacist-Assisted Therapy for Heart Failure

18+
All Sexes
Aurora, CO

Many Veterans who are hospitalized with heart failure do not receive all the recommended heart medications at the right doses before they leave the hospital or in the weeks following discharge. This study tests whether a team of clinical pharmacists and cardiologists, working virtually, can improve heart failure medication prescribing for Veterans at VA medical centers. The pharmacist and cardiologist team reviews patient records and provides recommendations to the treating doctors and primary care providers caring for Veterans with heart failure. The goal is to increase use of guideline-recommended medications, which have been shown to improve survival, reduce hospitalizations, and improve quality of life.

Waitlist Available
Has No Placebo

Rocky Mountain Regional VA Medical Center, Aurora, CO

Paul L Hess, MD MS

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Mobile Mindfulness for Psychological Distress in Critical Illness

18+
All Sexes
Los Angeles, CA

Serious acute heart and lung illnesses like heart failure, severe COVID, and sepsis often leave survivors struggling not only physically, but also with lasting depression, anxiety, and stress. These problems that are hard to treat because access to mental health care is often limited. To help address this, the researchers created Lift, a fully automated mindfulness program designed with patient input and delivered through a mobile app. The investigators now plan a large, multi-site study to test whether Lift improves mental health and quality of life over six months compared to a critical illness education program called Enlighten Recovery. Overall the goal is to make an easy-to-use, widely accessible program available to people across the U.S., including those who speak Spanish.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center (+2 Sites)

Christopher Cox, MD, MHA, MPH

Have you considered Lanoxicaps clinical trials?

We made a collection of clinical trials featuring Lanoxicaps, we think they might fit your search criteria.
Go to Trials
Image of Advanced Cardiovascular, LLC in Alexander City, United States.

NNC0487-0111 for Obesity and Heart Failure

18+
All Sexes
Alexander City, AL

This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.

Phase 3
Recruiting

Advanced Cardiovascular, LLC (+99 Sites)

Clinical Transparency (dept. 2834)

Novo Nordisk A/S

Image of Minneapolis Heart Institute Foundation in Minneapolis, United States.

Cardiac Resynchronization Therapy for Heart Failure

18+
All Sexes
Minneapolis, MN

This 2x2 randomized crossover feasibility study will evaluate the therapeutic value of adding pacing from the left ventricular lead to Left Bundle Branch Area Pacing (LBBAP) using a cardiac resynchronization therapy defibrillator (CRT-D). This combined therapy is known as Left Bundle Branch Optimized Cardiac Resynchronization Therapy (LOT-CRT) and will be compared to LBBAP therapy over sequential 6-month periods in CRT-indicated patients with LBBB. Primary and secondary outcomes are echocardiographic changes. Exploratory assessments will include NT-proBNP and subject-reported quality of life (KCCQ). An observational treatment arm will include subjects who have not been randomized due to unsuccessful implant for real-world observational analysis

Recruiting
Has No Placebo

Minneapolis Heart Institute Foundation

Medtronic Cardiac Rhythm and Heart Failure

Have you considered Lanoxicaps clinical trials?

We made a collection of clinical trials featuring Lanoxicaps, we think they might fit your search criteria.
Go to Trials